Metabotropic glutamate receptor 3 as a potential therapeutic target for psychiatric and neurological disorders.

Dogra, Shalini; Putnam, Jason; Conn, P Jeffrey

Dogra, Shalini; Putnam, Jason; Conn, P Jeffrey.

Afiliação

Dogra S; Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Putnam J; Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA.
Conn PJ; Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA; Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN 37232, USA. Electronic address: jeff.conn@vanderbilt.edu.

Pharmacol Biochem Behav ; 221: 173493, 2022 11.

Article em En | MEDLINE | ID: mdl-36402243

Assuntos

Doenças do Sistema Nervoso; Receptores de Glutamato Metabotrópico; Humanos; Doenças do Sistema Nervoso/tratamento farmacológico; Sistema Nervoso Central; Ácido Glutâmico

Palavras-chave

Antidepressants; Cognition; Depression; Glutamate; Neurodevelopmental disorders; Schizophrenia; Substance use disorders; mGlu3; mGlu5

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Glutamato Metabotrópico / Doenças do Sistema Nervoso Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google